Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study.
Journal: Leukemia & lymphoma
Published: December 13, 2025
Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices.
Journal: Current medical research and opinion
Published: December 20, 2024
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Journal: Annals of hematology
Published: March 27, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Journal: Targeted oncology
Published: March 10, 2024
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 08, 2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Journal: Leukemia & lymphoma
Published: January 15, 2021
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 15, 2020
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.
Journal: Research and practice in thrombosis and haemostasis
Published: August 18, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 15, 2020
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Journal: British journal of haematology
Published: April 17, 2019
Last Updated: 09/26/2026